Alexander Siebenhuner
Overview
Explore the profile of Alexander Siebenhuner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1015
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lehmann J, Dragan T, Rammant E, de Ligt K, Lai-Kwon J, Lidington E, et al.
Eur J Cancer
. 2025 Mar;
220:115333.
PMID: 40043551
Background: Using patient reported-outcome measures (PROMs) in routine care has significant potential to benefit patients with cancer, but it is unclear how widely they are used in practice. Methods: We...
2.
Stoffel S, Bhadhuri A, Salari P, Koeberle D, Koessler T, Siebenhuner A, et al.
BMJ Open
. 2025 Feb;
15(2):e090401.
PMID: 39987014
Objectives: Our study investigated the impact of oesophageal cancer and its treatments on work productivity, leisure time, household chores and informal care in Switzerland. We assessed indirect costs for patients...
3.
Kamp D, May A, Adenis A, Capela A, Derks S, De Felice F, et al.
Eur J Cancer
. 2025 Feb;
218:115278.
PMID: 39919335
Background: The enhanced application of imaging techniques is resulting in the diagnosis of more patients with asymptomatic metastatic esophagogastric cancer (mEGC). We conducted a Delphi study to gather insights from...
4.
Beck J, Siebenhuner A, Wild D, Christ E, Refardt J
Endocr Relat Cancer
. 2023 Dec;
31(3).
PMID: 38117915
Sex differences affect the management of several diseases in both male and female patients. However, the influence of sex on neuroendocrine neoplasms (NENs) has been scarcely investigated. Thus, this study...
5.
Schmidlin M, Sadowski S, Siebenhuner A, Wild D, Christ E, Refardt J
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190198
Typical (TC) and atypical carcinoids (AC) are the most common neuroendocrine tumors (NETs) of the lung. Because these tumors are rare, their management varies widely among Swiss centers. Our aim...
6.
Doswald S, Herzog A, Zeltner M, Zabel A, Pregernig A, Schlapfer M, et al.
Pharmaceutics
. 2022 Jul;
14(7).
PMID: 35890293
The count of circulating tumor cells (CTCs) has been associated with a worse prognosis in different types of cancer. Perioperatively, CTCs detach due to mechanical forces. Diagnostic tools exist to...
7.
Hirt C, Booij T, Grob L, Simmler P, Toussaint N, Keller D, et al.
Cell Genom
. 2022 Feb;
2(2):100095.
PMID: 35187519
Pancreatic cancer (PDAC) is a highly aggressive malignancy for which the identification of novel therapies is urgently needed. Here, we establish a human PDAC organoid biobank from 31 genetically distinct...
8.
Krug S, Khosravian M, Weissbach J, George K, Damm M, Garbe J, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158882
The assessment of cancer patient care during the COVID-19 pandemic has been mainly reported from a physician's perspective. Patients with rare tumor entities such as neuroendocrine tumors (NET), which require...
9.
Pfister D, Gonzalo Nunez N, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al.
Nature
. 2021 Mar;
592(7854):450-456.
PMID: 33762733
Hepatocellular carcinoma (HCC) can have viral or non-viral causes. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients...
10.
Pietge H, Sanchez-Velazquez P, Akhoundova D, Siebenhuner A, Winder T, Bachmann H, et al.
Oncology
. 2021 Mar;
99(5):300-309.
PMID: 33657549
Background: Unresectable cholangiocarcinoma has a poor prognosis and treatment options are limited. Combined systemic and intrahepatic chemotherapy may improve local control and enable downsizing. The aim of this study was...